期刊文献+

熊去氧胆酸治疗原发性胆汁性肝硬化的临床观察 被引量:6

A clinical observation of sixty primary biliary cirrhosis patients with ursodeoxycholic acid treatment
原文传递
导出
摘要 目的总结非肝硬化期原发性胆汁性肝硬化(primary biliary cirrhosis,PBC)的临床特点,评价熊去氧胆酸(UDCA)的疗效。方法回顾性分析60例非肝硬化期PBC患者治疗前及应用UDCA治疗12个月后的症状、体征、生化免疫学指标及肝脏瞬时弹性指标。结果本组患者临床分期为Ⅱ期31例,Ⅲ期29例。临床症状以黄疸(48.3%)、乏力(46.7%)、皮肤瘙痒(45.0%)为主。60例患者血清碱性磷酸酶(ALP)和γ-谷氨酰转肽酶(γ-GT)均升高,总胆红素(TBIL)升高29例(48.3%),丙氨酸氨基转移酶(ALT)及天冬氨酸氨基转移酶(AST)升高23例(38.3%),均为轻度升高;血清IgM升高58例(96.7%),抗线粒体抗体(AMA)阳性60例(100.0%),M2亚型阳性55例(91.7%)。经过UDCA规范治疗12个月后,ALT、AST、TBIL、ALP、γ-GT、IgA、IgM、IgG较治疗前均明显改善(P﹤0.05)。其中55例达到巴塞罗那生化应答标准,37例达到巴黎生化应答标准。Ⅱ期应答率高于Ⅲ期、巴塞罗那标准评价PBC患者的生化学应答率高于巴黎标准(P均﹤0.05)。治疗12个月后患者肝脏瞬时弹性指标较治疗前明显改善[(6.7±3.1)kPa vs.(7.8±3.8)kPa,P<0.05]。结论 PBC多见于中年女性,以乏力、黄疸、瘙痒为常见症状,血清ALP、γ-GT和IgM水平升高,AMA和(或)AMA-M2亚型阳性有助于PBC诊断。UDCA治疗能有效改善患者病情,对PBC早期患者治疗效果更加明显。 Objective To study the clinical feature of primary biliary cirrhosis(PBC) and to observe the efficacy by taking ursodeoxycholic acid (UDCA) treatment of 12 months. Methods General status, clinical manifestations and laboratory findings of 60 patients with PBC were analyzed. All patients were given UDCA for one year. Results Among 60 patients, 55 were females. The most frequent symptoms were jaundice(48.3%), fatigue(46.7%) and pruritus(45.0%). Serum alkaline phosphatase (ALP) and glutamyl transpetidase(γ-GT) levels were elevated in all patients. Twenty-nine patients (48.3%) had a total bilirubin level≥20 μmol/L, 23 patients(38.3%)had ALT /AST levels≥40 U/L. Fifty-eight patients(96.7%) had elevated serum IgM and all patients were anti-mitochondrial antibody positive and 55 patients (91.7%) were AMA-M2 positive. Thirty-one patients belonged to clinical Phase Ⅱ, 29 patients belonged to clinical Phase Ⅲ. When 60 patients finished the treatment with UDCA for one year, values of ALT、AST、TBIL、ALP、γ-GT、IgA、IgM and IgG were improved significantly. Fifty-five patients reached the Barcelona biochemical response standard, 37 patients reached Paris biochemical response criteria. The response rate of Phase Ⅱ in patients was better than Phase Ⅲ. Biochemical response rate of Barcelona standard evaluation was better than Paris standard(P 0.05). The Fibroscan was improved significantly after treatment[ (6.7±3.1) kPa vs. (7.8±3.8)kPa, P 0.05]. Conclusion PBC is mostly found in middle-aged women. The most frequent symptoms are pruritus,jaundice and fatigue. Elevated serum ALP and γ-GT levels together with positive AMA/AMA-M2 can help to diagnose PBC. Treatment with UDCA effectively improve the patient's biochemical markers.
出处 《北京医学》 CAS 2012年第3期177-180,共4页 Beijing Medical Journal
关键词 肝硬化 胆汁性 熊去氧胆酸 抗线粒体抗体 肝脏瞬时弹性超声 生化应答 Cirrhosis Biliary Ursodeoxycholic acid Anti mitochondrial antibody Fibroscan biochemical response
  • 相关文献

参考文献3

二级参考文献48

  • 1Heathcote E.Management of primary biliary cirrhosis.The American Association for the Study of liver disease practice guidelines.Hepatology,2000,31(4):1005-1013.
  • 2Poupon RE,Bonnand AM,Chretien Y,et al.Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis.Hepatology,1999,29(6):1668-1671.
  • 3Lazaridis KN,Gores G J,Lindor KD.Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders.J Hepatol,2001,35 (1):134-146.
  • 4Angulo P,Batts KP,Therneau TM,et al.Long term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.Hepatology,1999,29(3):644-647.
  • 5Goulis J,Leandro G,Burroughs AK.Randomized controlled trials of ursodeoxycholic acid therapy for primary biliary cirrhosis:a meta-analysis.Lancet,1999,354(9184):1053-1060.
  • 6Papatheodoridis GV,Hadziyannis,ES,Deutsch M,et al.Ursodeoycholic acid for primary biliary cirrhosis:final results of a 12-year,prospective,randomized,controlled trial.Am Gastroenterol,2002,97 (8):2063-2070.
  • 7Hagey LR,Crombie DL,Espinosa E,et al.Ursodoxycholic acid in the Ursidae:biliary bile acids of bears,pandas,and related carnivores.J Lipid Res,1993,34(11):1911-1917.
  • 8Beuers U,Boyer JL,Paumngartner G.Ursodeoxycholic acid in cholestasis:potential mechanism of action and therapeutic applications.Hepatolpgy,1998,28(5):1449-1453.
  • 9Paumgartner G,Beuers U.Ursodeoxycholic acid in cholestatic liver disease:mechanisms of action and therapeutic use revisited.Hepatology,2002,36(3):252-531.
  • 10Beuers U,Bilzer M,Chittattu A,et al.Tauroursodeoxycholic acid inserts the apical conjugate export pump,Mrp2,into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver.Hepatology,2001,33(5):1206-1216.

共引文献118

同被引文献42

  • 1李绍佐,丁贤君,徐方明,王晔恺,钱立勇,曾芳,李世波.熊去氧胆酸对急性肝损伤大鼠细胞因子和肝脏炎症的影响[J].中华临床感染病杂志,2013,6(3):181-183. 被引量:3
  • 2李继珩,许东,牟晓虹.牛磺熊去氧胆酸结构及性质的研究[J].中国药科大学学报,1993,24(3):145-149. 被引量:10
  • 3施健,刘苏,陈伟忠,曾欣,陈岳祥,杨秀疆,谢渭芬.中等剂量熊去氧胆酸治疗原发性胆汁性肝硬化的系统评价[J].中华消化杂志,2005,25(6):355-358. 被引量:30
  • 4Lindor KD, Gerslawin ME, Poupon R, et al. Primary biliary cir- rhosis[J]. Hepatology, 2009, 50:291-308.
  • 5EASL. Clinical Practice Guidelines : management of cholestat- ic liver diseases[J]. Hepatology, 2009, 51:237-267.
  • 6Honda A, Ikegami T, Nakamuta M, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid[J]. Hepatology, 2013, 57:1931-1941.
  • 7Heathcote EJ. Management of primary biliary cirrhosis. The Ame rican association for the study of liver diseases practice guide-lines[J]. Hepatology, 2000, 31:1005-1013.
  • 8Corpechot C, Abenavoli L, Rabahi N, et al. Biochemiealresponse to ursodeoxyeholic acid and long-term prognosis in primary bil- iary cirrhosis[J]. Hepatology, 2008, 48:871-877.
  • 9Oo YH, Neuberger J. Options for treatment of primary biliary cir- rhosis[J]. Drugs, 2004, 64:2261-2271.
  • 10Corpeehot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis :biochemical response to treatment and prediction of long-term outcome[J]. Hepatology, 2011, 55:1361-1367.

引证文献6

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部